{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:45:41Z","timestamp":1787928341696,"version":"build-2784847793"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) is a chronic immune-mediated intestinal disorder characterized by recurrent inflammation. Growing research over the last 10\u2009years has connected IBD to heightened heart-related danger, with major adverse cardiovascular events (MACE, including myocardial infarction (MI), ischemic heart disease (IHD), ischemic stroke) arising earlier in life without reliance on conventional risk elements like high blood pressure or abnormal lipid levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic literature search was performed in Medline, Embase, and the Cochrane Library to identify observational cohort and case\u2013control studies published from January 2015 through June 2025. Only original observational cohort and case\u2013control studies with adjusted outcome estimates were enrolled; systematic reviews, meta-analyses, Mendelian randomization studies, and preclinical studies were strictly excluded. Two independent reviewers extracted data and assessed methodological quality using the Newcastle\u2013Ottawa Scale. Meta-analysis was performed using random-effects models; forest plots were generated to visualize pooled effect estimates. Heterogeneity, sensitivity analyses, and publication bias were formally evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 3126 records were retrieved, and finally 12 eligible original observational studies (10 cohort studies, 2 case-control studies) were included, involving 3,017,580 participants and 204,328 IBD cases. Pooled results showed that IBD was significantly associated with increased risks of MI (hazard ratio (HR)\u2009=\u20091.41, 95% confidence interval (95%CI): 1.30\u20131.53,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200945%), IHD (HR\u2009=\u20091.37, 95%CI: 1.28\u20131.47,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200953%), and ischemic cerebrovascular accident (CVA; HR\u2009=\u20091.28, 95%CI: 1.19\u20131.38,\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200940%). Subgroup analysis indicated Crohn\u2019s disease had higher MI and IHD risks than ulcerative colitis; active IBD and patients under 40\u2009years also presented significantly elevated MACE risk. Additional subgroup analysis confirmed that high cumulative glucocorticoid exposure was independently associated with increased MACE risk (HR\/relative risk\u2009=\u20091.52, 95%CI: 1.31\u20131.76,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This meta-analysis confirms that IBD is independently associated with increased risk of MACE (MI, IHD, and ischemic CVA), with differential risks by subtype, disease activity, and age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10815589261473278","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:07:51Z","timestamp":1784884071000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Inflammatory bowel disease and cardiovascular risk: A meta-analysis"],"prefix":"10.1177","author":[{"given":"Lan","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First People\u2019s Hospital of Neijiang City, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First People\u2019s Hospital of Neijiang City, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Annese V Annunziata LM Petroni AG et al. Cardiovascular complications are increased in inflammatory bowel disease: a path toward achievement of a personalized risk estimation. J Pers Med 2025; 15(9): 418\u2013418. https:\/\/doi.org\/10.3390\/jpm15090418","DOI":"10.3390\/jpm15090418"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Fang L Gao H Gao X et al. Risks of cardiovascular events in patients with inflammatory bowel disease in China: a retrospective multicenter cohort study [J]. Inflamm Bowel Dis 2021; 28(S2): S52\u2013S58. https:\/\/doi.org\/10.1093\/ibd\/izab326","DOI":"10.1093\/ibd\/izab326"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Toscano A Blando G Patan\u00e8 L et al. Cardiovascular risk stratification in patients with inflammatory bowel disease: the role of non-invasive imaging and traditional risk scores [J]. Atherosclerosis 2025; 407(S): Article 120068. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120068","DOI":"10.1016\/j.atherosclerosis.2025.120068"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Ebrahimi R Ebrahimi F Niess HJ et al. Increased risk of cardiovascular events after coronary interventions in inflammatory bowel disease: a nationwide matched cohort study [J]. Aliment Pharmacol Ther 2025; 61(12): 1904\u20131912. https:\/\/doi.org\/10.1111\/apt.70162","DOI":"10.1111\/apt.70162"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Masson W Villar FG Elhelou MS. Management of atherosclerotic cardiovascular risk in inflammatory bowel disease: current perspectives [J]. Adv Ther 2025; 42(5): 2118\u20132134. https:\/\/doi.org\/10.1007\/S12325-025-03154-2","DOI":"10.1007\/s12325-025-03154-2"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Luo C Liu L Zhu D et al. Risk of stroke in patients with inflammatory bowel disease: a systematic review and meta-analysis [J]. BMC Gastroenterol 2025; 25(1): Article 114. https:\/\/doi.org\/10.1186\/S12876-025-03702-8","DOI":"10.1186\/s12876-025-03702-8"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Yang H An T Zhao Y et al. Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis [J]. Ann Med 2025; 57(1): Article 2455536. https:\/\/doi.org\/10.1080\/07853890.2025.2455536","DOI":"10.1080\/07853890.2025.2455536"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Heyman CN Chodick G. Inflammatory bowel disease is associated with an increased risk of cardiovascular events in a sex and age-dependent manner: a historical cohort study [J]. Int J Cardiol Cardiovasc Risk Prev 2025; 24: Article 200363. https:\/\/doi.org\/10.1016\/j.ijcrp.2025.200363","DOI":"10.1016\/j.ijcrp.2025.200363"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Yap MJ Wall LC Schultz M et al. The efficacy and feasibility of lifestyle interventions on modifiable cardiovascular disease risk factors among people with inflammatory bowel disease [J]. Proc Nutr Soc 2025; 84: 168\u2013175. https:\/\/doi.org\/10.1017\/S0029665124007596","DOI":"10.1017\/S0029665124007596"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Liu FL Fan WY Lv Y et al. Strategies for assessing and preventing cardiovascular disease risk in inflammatory bowel disease patients: a meta-analysis and meta-regression and bibliometric review [J]. PLoS One 2025; 20(7): e0327734. https:\/\/doi.org\/10.1371\/journal.pone.0327734","DOI":"10.1371\/journal.pone.0327734"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Song E Qi Y Singh S. Prevalence of ORAL surveillance-like cardiovascular risk factors in adults patients with inflammatory bowel diseases: national estimates from the United States [J]. Gastro Hep Adv 2025; 4(10): Article 100723. https:\/\/doi.org\/10.1016\/j.gastha.2025.100723","DOI":"10.1016\/j.gastha.2025.100723"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez MI Carpio D Hern\u00e1ndez V et al. Spanish Working Group in Crohn\u2019s disease and ulcerative colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease [J]. Gastroenterol Hepatol 2024; 48(5): Article 502314. https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502314","DOI":"10.1016\/j.gastre.2025.502314"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Wu Y Xu W. Refining metabolic health assessment in inflammatory bowel disease risk prediction [J]. Eur J Intern Med 2024; 134: 148\u2013149. https:\/\/doi.org\/10.1016\/j.ejim.2024.10.020","DOI":"10.1016\/j.ejim.2024.10.020"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Livzan AM Bikbavova RG Lisyutenko SN et al. Cardiovascular risk in patients with inflammatory bowel diseases\u2014the role of endothelial dysfunction [J]. Diagnostics 2024; 14(16): Article 1722. https:\/\/doi.org\/10.3390\/diagnostics14161722","DOI":"10.3390\/diagnostics14161722"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Iqbal O Shah H Sosa A et al. Coronary artery calcium score for cardiovascular risk assessment in inflammatory bowel disease\u2014data from first pilot prospective study [J]. Digest Liver Dis 2024; 56(11): 1965\u20131967. https:\/\/doi.org\/10.1016\/j.dld.2024.07.019","DOI":"10.1016\/j.dld.2024.07.019"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Greywoode R Larson J Peraza J et al. Risk of adverse cardiovascular outcomes in postmenopausal women with inflammatory bowel disease [J]. Digest Dis Sci 2024; 69(7): 2586\u20132594. https:\/\/doi.org\/10.1007\/S10620-024-08348-2","DOI":"10.1007\/s10620-024-08348-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Raju VKA Pathiyil MM Abraham MG. Risk of cardiovascular disease in patients with inflammatory bowel disease: a systematic review and meta-analysis [J]. J Am Coll Cardiol 2024; 83(13S): 1312. https:\/\/doi.org\/10.1016\/S0735-1097(24)03302-3","DOI":"10.1016\/S0735-1097(24)03302-3"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Chaudhry RAW Ashfaq M Kaur P et al. Cardiovascular risk assessment in inflammatory bowel disease with coronary calcium score [J]. Ann Med Surg (2012) 2024; 86(3): 1496\u20131505. https:\/\/doi.org\/10.1097\/MS9.0000000000001652","DOI":"10.1097\/MS9.0000000000001652"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Mateo GS Dom\u00ednguez MJS Puyuelo GJC et al. Cardiovascular risk assessment in inflammatory bowel disease with metabolic dysfunction-associated steatotic liver disease [J]. Med Clin 2024; 162(9): 409\u2013416. https:\/\/doi.org\/10.1016\/j.medcli.2023.11.032","DOI":"10.1016\/j.medcli.2023.11.032"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Dwivedi KA. Step-by-step guide and checklists for selecting and conducting an evidence synthesis study using a framework for approaches and methods in evidence synthesis (FRAMES) [J]. PeerJ 2026; 14(20): 89\u201397. https:\/\/doi.org\/10.7717\/peerj.20897","DOI":"10.7717\/peerj.20897"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Panhwar MS Mansoor E Al-Kindi SG et al. Risk of myocardial infarction in inflammatory bowel disease: a population-based national study. Inflamm Bowel Dis 2019; 25(6): 1080\u20131087. https:\/\/doi.org\/10.1093\/ibd\/izy354","DOI":"10.1093\/ibd\/izy354"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Rungoe C Basit S Ranthe MF et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2013; 62(5): 689\u2013694. https:\/\/doi.org\/10.1136\/gutjnl-2012-303285","DOI":"10.1136\/gutjnl-2012-303285"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Ghoneim S Shah A Dhorepatil A et al. The risk of cerebrovascular accidents in inflammatory bowel disease in the United States: a population-based national study. Clin Exp Gastroenterol 2020; 13: 123\u2013129. https:\/\/doi.org\/10.2147\/ceg.s250182","DOI":"10.2147\/CEG.S250182"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Gu Y Lou Y Zhou Z et al. Resveratrol for inflammatory bowel disease in preclinical studies: a systematic review and meta-analysis. Front Pharmacol 2024; 15: Article 1411566. https:\/\/doi.org\/10.3389\/fphar.2024.1411566","DOI":"10.3389\/fphar.2024.1411566"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Wan J Wang X Zhang YJ et al. Incidence and disease-related risk factors for cerebrovascular accidents in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Dig Dis 2023; 24(10): 504\u2013515. https:\/\/doi.org\/10.1111\/1751-2980.13232","DOI":"10.1111\/1751-2980.13232"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Filimon AM Negreanu L Doca M et al. Cardiovascular involvement in inflammatory bowel disease: dangerous liaisons. World J Gastroenterol 2015; 21(33): 9688\u20139692. https:\/\/doi.org\/10.3748\/wjg.v21.i33.9688","DOI":"10.3748\/wjg.v21.i33.9688"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Song Y Zou X Zeng Y et al. Inflammatory bowel disease and the risk of intracerebral hemorrhage: a Mendelian randomization study and meta-analysis. Immun Inflamm Dis 2023; 11(10): Article e1048. https:\/\/doi.org\/10.1002\/iid3.1048","DOI":"10.1002\/iid3.1048"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Singh S Singh H Loftus EVJr et al. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12(3): 382\u2013393.e1: quiz e22. https:\/\/doi.org\/10.1016\/j.cgh.2013.08.023","DOI":"10.1016\/j.cgh.2013.08.023"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Jaiswal V Batra N Dagar M et al. Inflammatory bowel disease and associated cardiovascular disease outcomes: a systematic review. Medicine (Baltimore) 2023; 102(6): Article e32775. https:\/\/doi.org\/10.1097\/md.0000000000032775","DOI":"10.1097\/MD.0000000000032775"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Sun HH Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis. Eur J Prev Cardiol 2018; 25(15): 1623\u20131631. https:\/\/doi.org\/10.1177\/2047487318792952","DOI":"10.1177\/2047487318792952"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Czubkowski P Osiecki M Szyma\u0144ska E et al. The risk of cardiovascular complications in inflammatory bowel disease. Clin Exp Med 2020; 20(4): 481\u2013491. https:\/\/doi.org\/10.1007\/s10238-020-00639-y","DOI":"10.1007\/s10238-020-00639-y"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Quazim A Loftus EV Yarur A et al. Inflammatory bowel disease is associated with an increased risk of incident acute arterial events: analysis of the United Kingdom Biobank [J]. Clin Gastroenterol Hepatol 2022; 21(3): 761\u2013770.e13. https:\/\/doi.org\/10.1016\/j.cgh.2022.08.035","DOI":"10.1016\/j.cgh.2022.08.035"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Sleutjes JAM Roeters Van Lennep JE Kavousi M et al. Increased risk of cardiovascular disease and high risk profiles compatible with metabolic syndrome in patients with inflammatory bowel disease: a cross-sectional analysis of matched cohorts [J]. Atherosclerosis 2022; 355: 250. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.06.958","DOI":"10.1016\/j.atherosclerosis.2022.06.958"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"Ecaterina AJ Otilia G Mihaela D et al. Ischemic heart disease in patients with inflammatory bowel disease: risk factors mechanisms and prevention [J]. Life (Basel Switzerland) 2022; 12(8): Article 1113. https:\/\/doi.org\/10.3390\/life12081113","DOI":"10.3390\/life12081113"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","unstructured":"Sleutjes JAM Roeters van Lennep JE de Vries AC. Spotlight on cardiovascular risk assessment in patients with inflammatory bowel disease [J]. Digest Dis Sci 2022; 67(9): 4326\u20134329. https:\/\/doi.org\/10.1007\/S10620-022-07449-0","DOI":"10.1007\/s10620-022-07449-0"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","unstructured":"Kochar BD Cheng D Cai T et al. Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases [J]. Digest Dis Sci 2022; 67(11): 1\u20137. https:\/\/doi.org\/10.1007\/S10620-022-07404-Z","DOI":"10.1007\/s10620-022-07404-z"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","unstructured":"Angelina C Sadie S Adam R et al. Inflammatory bowel disease risk stratification and management in a community practice setting [J]. Gastroenterology 2022; 162(3S): S33\u2013S34. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.069","DOI":"10.1053\/j.gastro.2021.12.069"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","unstructured":"Nasir K Acquah I Dey AK et al. Inflammatory bowel disease and atherosclerotic cardiovascular disease in U.S. adults\u2014a population-level analysis in the national health interview survey [J]. Am J Prev Cardiol 2022; 9(10): Article 100316. https:\/\/doi.org\/10.1016\/j.ajpc.2022.100316","DOI":"10.1016\/j.ajpc.2022.100316"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","unstructured":"Alayo AQ Famutimi D Ayoub M et al. Performance of ASCVD risk prediction models in individuals with inflammatory bowel disease: a UK biobank study [J]. Inflamm Bowel Dis 2024; 18(3): 23\u201329. https:\/\/doi.org\/10.1093\/ibd\/izae007","DOI":"10.1093\/ibd\/izae007"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Soares CA Fiuza JG Rodrigues CAM et al. Inflammatory bowel disease and cardiac function: a systematic review of literature with meta-analysis [J]. Therap Adv Gastroenterol 2024; 17(17): 56\u201364. https:\/\/doi.org\/10.1177\/17562848241299534","DOI":"10.1177\/17562848241299534"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","unstructured":"\u0141ykowska-Szuber L Rychter AM Dudek M et al. What links an increased cardiovascular risk and inflammatory bowel disease? A narrative review [J]. Nutrients 2021; 13(8): 2661\u20132668. https:\/\/doi.org\/10.3390\/nu13082661","DOI":"10.3390\/nu13082661"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","unstructured":"Preetika S Raymond C. Cardiovascular risk assessment and impact of medications on cardiovascular disease in inflammatory bowel disease [J]. Inflamm Bowel Dis 2021; 27(7): 1107\u20131115. https:\/\/doi.org\/10.1093\/ibd\/izaa258","DOI":"10.1093\/ibd\/izaa258"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Principi M Scicchitano P Carparelli S et al. Influence of systemic manifestations of inflammatory bowel diseases on endothelial function and cardiovascular risk [J]. Minerva Med 2021; 113(2): 291\u2013299. https:\/\/doi.org\/10.23736\/S0026-4806.21.06970-6","DOI":"10.23736\/S0026-4806.21.06970-6"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","unstructured":"Nu\u00f1ez P Mateo SG Quera R et al. Inflammatory bowel disease and the risk of cardiovascular diseases [J]. Gastroenterol Hepatol (English Edition) 2021; 44(3): 12\u201320. https:\/\/doi.org\/10.1016\/j.gastre.2021.02.003","DOI":"10.1016\/j.gastre.2021.02.003"}],"container-title":["Journal of Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589261473278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10815589261473278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589261473278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T07:49:04Z","timestamp":1787298544000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10815589261473278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":44,"alternative-id":["10.1177\/10815589261473278"],"URL":"https:\/\/doi.org\/10.1177\/10815589261473278","relation":{},"ISSN":["1081-5589","1708-8267"],"issn-type":[{"value":"1081-5589","type":"print"},{"value":"1708-8267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"10815589261473278"}}